Sheaff Brock Investment Advisors LLC acquired a new stake in Neos Therapeutics, Inc. (NASDAQ:NEOS) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 100,000 shares of the company’s stock, valued at approximately $915,000. Sheaff Brock Investment Advisors LLC owned approximately 0.34% of Neos Therapeutics at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of NEOS. Russell Investments Group Ltd. boosted its holdings in shares of Neos Therapeutics by 167.9% in the second quarter. Russell Investments Group Ltd. now owns 270,020 shares of the company’s stock valued at $1,971,000 after acquiring an additional 169,237 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its stake in Neos Therapeutics by 103.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 43,700 shares of the company’s stock valued at $320,000 after purchasing an additional 22,200 shares during the last quarter. Rhumbline Advisers lifted its stake in Neos Therapeutics by 13.6% during the second quarter. Rhumbline Advisers now owns 20,409 shares of the company’s stock valued at $149,000 after purchasing an additional 2,441 shares during the last quarter. Falcon Point Capital LLC lifted its stake in Neos Therapeutics by 37.7% during the second quarter. Falcon Point Capital LLC now owns 121,563 shares of the company’s stock valued at $887,000 after purchasing an additional 33,284 shares during the last quarter. Finally, State of Wisconsin Investment Board acquired a new stake in Neos Therapeutics during the second quarter valued at approximately $102,000. Institutional investors and hedge funds own 45.93% of the company’s stock.

Shares of Neos Therapeutics, Inc. (NEOS) opened at $9.70 on Tuesday. Neos Therapeutics, Inc. has a one year low of $4.85 and a one year high of $13.15. The company has a debt-to-equity ratio of 4.01, a current ratio of 2.42 and a quick ratio of 2.14.

Neos Therapeutics (NASDAQ:NEOS) last released its earnings results on Wednesday, November 8th. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.22. The business had revenue of $6.70 million during the quarter. Neos Therapeutics had a negative net margin of 339.52% and a negative return on equity of 551.26%. equities research analysts forecast that Neos Therapeutics, Inc. will post -2.87 earnings per share for the current fiscal year.

Several analysts recently commented on NEOS shares. Royal Bank Of Canada set a $12.00 target price on shares of Neos Therapeutics and gave the company an “outperform” rating in a research note on Tuesday, August 8th. Cantor Fitzgerald set a $20.00 target price on shares of Neos Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 9th. ValuEngine raised shares of Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 12th. Zacks Investment Research raised shares of Neos Therapeutics from a “hold” rating to a “strong-buy” rating and set a $8.00 target price for the company in a research note on Wednesday, August 23rd. Finally, Wells Fargo & Company set a $14.00 target price on shares of Neos Therapeutics and gave the company a “buy” rating in a research note on Wednesday, October 18th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. Neos Therapeutics has an average rating of “Buy” and a consensus target price of $14.00.

TRADEMARK VIOLATION WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.watchlistnews.com/sheaff-brock-investment-advisors-llc-invests-915000-in-neos-therapeutics-inc-neos/1744751.html.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Institutional Ownership by Quarter for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.